HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

New Nrf2-Inducer Compound ITH12674 Slows the Progression of Retinitis Pigmentosa in the Mouse Model rd10.

AbstractBACKGROUND/AIMS:
It is well established that oxidative stress and inflammation are common pathogenic features of retinal degenerative diseases. ITH12674 is a novel compound that induces the transcription factor Nrf2; in so doing, the molecule exhibits anti-inflammatory, and antioxidant properties, and affords neuroprotection in rat cortical neurons subjected to oxidative stress. We here tested the hypothesis that ITH12674 could slow the retinal degeneration that causes blindness in rd10 mice, a model of retinitis pigmentosa.
METHODS:
Animals were intraperitoneally treated with 1 or 10 mg/Kg ITH12674 or placebo from P16 to P30. At P30, retinal functionality and visual acuity were analyzed by electroretinography and optomotor test. By immunohistochemistry we quantified the photoreceptor rows and analyzed their morphology and connectivity. Oxidative stress and inflammatory state was studied by Western blot, and microglia reactivity was monitored by flow cytometry. The blood-brain barrier permeation of ITH12674 was evaluated using a PAMPA-BBB assay.
RESULTS:
In rd10 mice treated with 10 mg/Kg of the compound, the following changes were observed (with respect to placebo): (i) a decrease of vision loss with higher scotopic a- and b-waves; (ii) increased visual acuity; (iii) preservation of cone photoreceptors morphology, as well as their synaptic connectivity; (iv) reduced expression of TNF-α and NF-κB; (v) increased expression of p38 MAPK and Atg12-Atg5 complex; and (vi) decreased CD11c, MHC class II and CD169 positive cell populations.
CONCLUSION:
These data support the view that a Nrf2 inducer compound may arise as a new therapeutic strategy to combat retinal neurodegeneration. At present, we are chemically optimising compound ITH12674 with the focus on improving its neuroprotective potential in retinal neurodegenerative diseases.
AuthorsLaura Campello, Oksana Kutsyr, Agustina Noailles, Patrycja Michalska, Laura Fernández-Sánchez, Natalia Martínez-Gil, Isabel Ortuño-Lizarán, Xavier Sánchez-Sáez, Emilio de Juan, Pedro Lax, Rafael León, Antonio G García, Nicolás Cuenca, Victoria Maneu
JournalCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology (Cell Physiol Biochem) Vol. 54 Issue 1 Pg. 142-159 (Feb 07 2020) ISSN: 1421-9778 [Electronic] Germany
PMID32028545 (Publication Type: Journal Article)
Copyright© Copyright by the Author(s). Published by Cell Physiol Biochem Press.
Chemical References
  • ITH12674
  • Isothiocyanates
  • NF-E2-Related Factor 2
  • Tumor Necrosis Factor-alpha
  • p38 Mitogen-Activated Protein Kinases
  • Melatonin
Topics
  • Animals
  • Blood-Brain Barrier (drug effects, metabolism)
  • Disease Models, Animal
  • Electroretinography
  • Female
  • Gene Expression Regulation (drug effects)
  • Isothiocyanates (chemistry, pharmacology, therapeutic use)
  • Male
  • Melatonin (analogs & derivatives, chemistry, pharmacology, therapeutic use)
  • Mice
  • Mice, Inbred C57BL
  • NF-E2-Related Factor 2 (agonists, metabolism)
  • Photoreceptor Cells (drug effects, pathology)
  • Retina (drug effects, metabolism)
  • Retinitis Pigmentosa (drug therapy, metabolism, pathology)
  • Tumor Necrosis Factor-alpha (metabolism)
  • Visual Acuity (drug effects)
  • p38 Mitogen-Activated Protein Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: